A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large Bcell lymphoma (DLBCL), and multiple myeloma (MM)

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: c5261de8df6f8f815ca81190b12036ae8b950948
First added on: Feb 14, 2025